Relay Therapeutics (RLAY) Competitors $6.11 +0.28 (+4.80%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$6.13 +0.02 (+0.34%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLAY vs. ACAD, ZLAB, AAPG, LNTH, TLX, NAMS, CNTA, AMRX, QURE, and XENEShould you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include ACADIA Pharmaceuticals (ACAD), Zai Lab (ZLAB), Ascentage Pharma Group International (AAPG), Lantheus (LNTH), Telix Pharmaceuticals (TLX), NewAmsterdam Pharma (NAMS), Centessa Pharmaceuticals (CNTA), AMNEAL PHARMACEUTICALS (AMRX), uniQure (QURE), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry. Relay Therapeutics vs. Its Competitors ACADIA Pharmaceuticals Zai Lab Ascentage Pharma Group International Lantheus Telix Pharmaceuticals NewAmsterdam Pharma Centessa Pharmaceuticals AMNEAL PHARMACEUTICALS uniQure Xenon Pharmaceuticals Relay Therapeutics (NASDAQ:RLAY) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Does the media favor RLAY or ACAD? In the previous week, ACADIA Pharmaceuticals had 15 more articles in the media than Relay Therapeutics. MarketBeat recorded 15 mentions for ACADIA Pharmaceuticals and 0 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.67 beat ACADIA Pharmaceuticals' score of 0.24 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Relay Therapeutics Very Positive ACADIA Pharmaceuticals Neutral Which has more risk and volatility, RLAY or ACAD? Relay Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Which has higher earnings and valuation, RLAY or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelay Therapeutics$10.01M105.24-$337.71M-$1.95-3.13ACADIA Pharmaceuticals$957.80M3.75$226.45M$1.3316.02 Do institutionals and insiders believe in RLAY or ACAD? 97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 4.9% of Relay Therapeutics shares are held by insiders. Comparatively, 26.5% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer RLAY or ACAD? Relay Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 170.05%. ACADIA Pharmaceuticals has a consensus target price of $29.12, suggesting a potential upside of 36.64%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Relay Therapeutics is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78ACADIA Pharmaceuticals 1 Sell rating(s) 7 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.62 Is RLAY or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 21.80% compared to Relay Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relay TherapeuticsN/A -41.49% -37.43% ACADIA Pharmaceuticals 21.80%14.69%9.41% SummaryACADIA Pharmaceuticals beats Relay Therapeutics on 10 of the 16 factors compared between the two stocks. Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLAY vs. The Competition Export to ExcelMetricRelay TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.01B$2.62B$6.09B$10.54BDividend YieldN/A56.71%5.69%4.71%P/E Ratio-3.1323.6985.5627.61Price / Sales105.24571.62535.65201.06Price / CashN/A173.2337.9261.55Price / Book1.315.5313.036.76Net Income-$337.71M$32.78M$3.30B$275.88M7 Day Performance17.05%5.82%4.35%2.81%1 Month Performance50.12%13.16%9.50%9.24%1 Year Performance-4.68%1.69%85.16%35.42% Relay Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLAYRelay Therapeutics2.8201 of 5 stars$6.11+4.8%$16.50+170.0%-2.2%$1.01B$10.01M-3.13330Positive NewsACADACADIA Pharmaceuticals4.4719 of 5 stars$21.32+1.3%$29.12+36.6%+47.4%$3.55B$957.80M16.03510Analyst RevisionZLABZai Lab2.5634 of 5 stars$32.93+4.1%$56.35+71.1%+35.6%$3.53B$398.99M-16.141,869News CoveragePositive NewsAnalyst ForecastAAPGAscentage Pharma Group InternationalN/A$38.55+3.3%N/AN/A$3.48B$134.35M0.00600News CoveragePositive NewsGap UpLNTHLantheus4.6478 of 5 stars$50.62+0.0%$85.50+68.9%-50.5%$3.44B$1.53B13.46700Trending NewsAnalyst DowngradeGap DownTLXTelix Pharmaceuticals4.4741 of 5 stars$9.89-0.9%$21.00+112.3%N/A$3.38B$516.72M0.00N/AAnalyst UpgradeNAMSNewAmsterdam Pharma3.1859 of 5 stars$27.52-3.4%$42.00+52.6%+85.2%$3.21B$45.56M0.004Analyst ForecastCNTACentessa Pharmaceuticals3.035 of 5 stars$24.40+4.9%$32.38+32.7%+38.7%$3.11B$6.85M-13.63200Analyst ForecastAMRXAMNEAL PHARMACEUTICALS2.7895 of 5 stars$9.87+1.2%$12.00+21.6%+21.0%$3.06B$2.79B14.558,100Analyst ForecastQUREuniQure3.5331 of 5 stars$59.40+9.4%$67.17+13.1%+913.0%$2.98B$27.12M-15.15500Trending NewsAnalyst ForecastAnalyst RevisionXENEXenon Pharmaceuticals2.892 of 5 stars$39.06+2.8%$53.30+36.5%-4.3%$2.93B$9.43M-11.00210Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies ACAD Alternatives ZLAB Alternatives AAPG Alternatives LNTH Alternatives TLX Alternatives NAMS Alternatives CNTA Alternatives AMRX Alternatives QURE Alternatives XENE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLAY) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
